Because IGF-IR regulates the production of VEGF ligands in GC cells and contributes to angiogenesis and lymphangiogenesis, inhibiting the IGF-I receptor can increase the antitumor impact of bevacizumab [91]. Here, VEGFA is linked to gastric cancer.